{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000031","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.008512+00:00","generated_at":"2026-06-18T23:44:03.680687+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BeiGene Q4 product revenue $339M (+72% YoY); BRUKINSA sales $176M (+101%); tislelizumab gets 10th China approval","bullets":["Product revenue $339M Q4, $1.3B FY2022, up 72% and 98% YoY; net loss $445M Q4, $2.0B FY.","BRUKINSA global sales $176M Q4 (+101%), $565M FY (+159%); U.S. sales $125M Q4 (+124%).","Tislelizumab China sales $102M Q4 (+88%), $423M FY (+66%); NMPA approved 10th indication for first-line gastric cancer.","Cash $4.5B at Dec 31, 2022; operating cash burn $1.5B FY.","BRUKINSA received U.S. FDA approval for CLL/SLL in Jan 2023; EC approval for CLL."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000031","json":"https://secwatch.observer/filing/0001651308-23-000031.json","markdown":"https://secwatch.observer/filing/0001651308-23-000031.md","text":"https://secwatch.observer/filing/0001651308-23-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/0001651308-23-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/bgne-20230224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:44:03.680687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56adea4d89f40b73a98e8804d25f885af4383285","claim":"BeOne Medicines Ltd. reported full year 2022 results: revenue $1.4 billion.","evidence_excerpt":"Revenue for the fourth quarter and full year 2022 was $380.1 million and $1.4 billion, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/0001651308-23-000031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$1.4 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c5373c07cac2b66d18d69034babf6df6148669c1","claim":"BeOne Medicines Ltd. reported fourth quarter 2022 results: revenue $380.1 million.","evidence_excerpt":"Revenue for the fourth quarter and full year 2022 was $380.1 million and $1.4 billion, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/0001651308-23-000031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2022"},{"label":"Revenue","value":"$380.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}